AB0366 "I JUST WANT MY LIFE BACK": PHYSICAL FUNCTION AND FATIGUE ARE CRITICAL TARGETS FOR IMPROVING PARTICIPATION AND HRQL IN RHEUMATOID ARTHRITIS
Results: Participants were mostly female (82%) and white (83%) with mean (SD) age of 56 (13) years; 24% had ≤ high school, 29% had RA ≤5 years with 13% ≤2 years, and 22% were disabled. Mean CDAI was 7.9 (7.8). Most were in CDAI remission (n=56; 32%) or LDA (n=67; 38%); 39 (22%) were in MDA and 14 (8%) in HDA. Mean PROMIS fatigue was 53.9 (10.0); fatigue increased across CDAI levels from 46.2 (8.6) in remission to 64.0 (9.6). Only those with HDA had mean sleep, depression or anxiety scores >55 (i.e., above population norms). In the full model, fatigue, depression, CDAI, and physical function were significant independent predictors of reduced participation in social roles and activities (F (2, 162) =29.75, p<.001, adjusted r 2 =.55). Contrary to our hypothesis, pain was not associated with participation in univariate or multivariate models. Conclusions: Our results suggest that in RA patients, high levels or fatigue are common; conversely, depression, anxiety, and sleep disturbance were elevated only in people with HDA. Disability and fatigue appear to have the greatest impact on participation in social roles and activities. RA treatments and interventions that attenuate fatigue and improve mood in people with active RA may improve their ability to participate in social and life situations restoring a sense of normalcy and improving HRQL. Background: Cases with Pneumocystis pneumonia (PCP) have been reported in patients with rheumatoid arthritis, mainly treated with biologics. An experimental study in the mouse revealed that sulfasalazine enhances the clearance of the Pneumocystis organism from the lung (1). Furthermore, a case-control study with small sample size indicated possible preventive effect of sulfasalazine against PCP (2). Objectives: The aim of this study is to clarify the prophylactic effect of sulfasalazine against PCP in patients with rheumatoid arthritis with a large sample size. Methods: This retrospective study focused on all patients with rheumatoid arthritis seen between April, 2011 and October, 2016 . at department of rheumatology, Tokyo Metropolitan Tama Medical Center. We investigated their demographics and medication, including corticosteroids, disease-modifying antirheumatic drugs and prophylactic drugs against PCP. The person-time at risk was calculated from prescription records. We compared the incidence during the period of follow-up in which the patients received sulfasalazine with that in which they did not received sulfasalazine. The incidents were assumed to follow a Poisson distribution and statistical analysis was performed using z-test. Results: In the study period, 2,394 patients with rheumatoid arthritis were treated at our hospital. Among them, 24 patients received the treatment for PCP because the infection was diagnosed or was strongly suspected. All the cases developed the condition while they were not taking sulfasalazine. The incidence rate of PCP was significantly lower in the treatment period with sulfasalazine than that without sulfasalazine (p<0.001). Conclusions: Our study confirmed that sulfasalazine has a preventive effect against PCP in patients with rheumatoid arthritis. 
